Riachol

Chloramphenicol

Method of action: Bacteriostatic, Ophthalmologicals

Treatment option: Abscess, Brain Abscess, Brucellosis, Influenza, Dysentery, Skin Conditions, Infection, Carbuncle, Fever, Peritonitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Riachol

What is Riachol? Defining the Active Ingredient and Class

Property	Description
Active ingredient	Chloramphenicol
Form	Systemic (Oral, Parenteral) and Topical (Ophthalmic) preparations
Pharmacological class	Amphenicol-class Antibacterial
General purpose	Controlling severe bacterial infections
Origin	Synthetic antimicrobial agent

Riachol refers to medicinal preparations containing Chloramphenicol, an active ingredient officially classified as an Amphenicol-class Antibacterial. This substance is defined as a potent, broad-spectrum antibiotic used to control a wide range of bacterial pathogens.

Chloramphenicol is historically significant as the first bulk-produced synthetic antimicrobial agent, initially isolated from Streptomyces venezuelae but now manufactured chemically. Pharmacological studies and clinical experience have consistently supported its efficacy. The drug remains a critically important antimicrobial, demonstrating its distinctive and vital role in global health where alternative antibiotics may be unavailable or ineffective.

Riachol's General Purpose and Formulations

The fundamental purpose of Riachol is to control the spread of bacterial infections by stopping the microbes from growing and multiplying. It functions as a bacteriostatic agent, which means it interferes with bacterial protein synthesis by targeting the 50S ribosomal subunit, essentially freezing the infection's development and allowing the patient's immune system to clear the pathogen. A typical use scenario involves treating serious infections caused by susceptible organisms where the unique mechanism of Chloramphenicol is necessary.

The drug is manufactured in various identity-level forms to ensure effective delivery. These preparations include oral solid forms, oral liquid preparations, and parenteral solutions administered for systemic administration throughout the body. Additionally, the drug is available in specialized topical/ophthalmic preparations, such as eye drops or ointments, a key differentiating factor that allows for localized treatment of sensitive areas.

Regulatory References

What side effects are possible with Riachol?

Possible Side Effects and Safety Information

The safety profile of Riachol focuses on the risk of severe blood disorders and specific toxicity risks in vulnerable patient groups, as documented in regulatory sources.

Adverse Reactions and System-Organ Class Involvement

Adverse reactions documented in official sources primarily affect the Blood and Lymphatic System and the Nervous System.

Key adverse reactions include:

Hematological (Blood) Disorders: This category involves two distinct patterns: an unpredictable, potentially fatal, and irreversible form known as aplastic anemia; and a more common, dose-related, reversible bone marrow suppression (leading to mild anemia).
Nervous System Disorders: Documented neurotoxicity includes reports of peripheral neuropathy and optic neuritis, which may necessitate immediate discontinuation of the medication.
Gastrointestinal Disorders: Reactions may involve nausea, vomiting, or diarrhea.

Serious Safety Considerations and Limitations

Serious Adverse Reactions highlight the potential for severe outcomes, including the risk of fatal aplastic anemia and Grey baby syndrome in neonates and infants, which is associated with cardiovascular collapse due to high plasma concentrations.

Population-Specific Safety Considerations apply to several groups:

Neonates and Infants: The medication is generally avoided in neonates and infants due to the high risk of Grey baby syndrome.
Other Populations: Careful monitoring of drug plasma concentrations is required for elderly patients and individuals with hepatic impairment to manage toxicity risks.

Safety-Related Restrictions and Contraindications specify conditions under which the medication must not be used:

Known hypersensitivity (allergy) to Riachol.
Pre-existing acute porphyria.
Use in neonates less than one week old.

This structure reflects the regulatory documentation, which guides the understanding of risks by categorizing them into dose-related, reversible effects and rare, idiosyncratic, and potentially life-threatening events.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Riachol is defined by a risk of severe systemic toxicity, often associated with elevated serum chloramphenicol concentrations that exceed the accepted therapeutic range. Documented manifestations of systemic overdose may include gastrointestinal disturbances such as nausea, vomiting, and abdominal distension. More severe clinical findings involve neurological effects (confusion, headache, or coma), temperature dysregulation leading to hypothermia, and circulatory compromise characterized by hypotension and cardiovascular collapse.

The regulatory documents identify a distinct, life-threatening risk in infants known as Gray Syndrome, which is classified as a frequently fatal toxic reaction. This syndrome is marked by the rapid progression of symptoms, including pallid cyanosis (ashen-gray discoloration of the skin), irregular respiration, and vasomotor collapse. This high-risk profile is due to the immature hepatic metabolism in neonates and premature infants, and the risk is also noted for patients with hepatic impairment.

Management for suspected systemic overdose is symptomatic and supportive. Regulators mandate the termination of therapy upon the early evidence of toxicity. Immediate medical attention must be sought for any signs associated with Gray Syndrome or severe collapse. Management requires continuous monitoring of serum chloramphenicol concentrations and may include procedural interventions, such as hemodialysis or exchange transfusion.

Therapeutic Uses of Riachol

What Riachol Treats: Main Uses and Benefits

Riachol (Chloramphenicol) is commonly used across domains involving significant symptomatic burden, especially in situations requiring supportive symptom management for severe systemic infections. This medication is applied in scenarios where additional management of discomfort is required, particularly when the infection is caused by organisms where other treatments may be less appropriate. The medication supports the patient during difficult episodes by easing distress related to systemic imbalance and symptoms that create noticeable physiological strain.

The medication may be part of symptomatic management for symptoms of increased neurological activity characteristic of severe CNS infections, and is applied in addressing conditions marked by increased physiological stress, such as Typhoid fever, bacterial Meningitis, and specific Rickettsial diseases. Furthermore, it is relevant in contexts involving heightened systemic burden linked to conditions where functional stability becomes affected. “It assists with maintaining functional stability when symptoms interfere with daily functioning,” as relief from symptoms related to systemic imbalance and physical discomfort contributes to easing the overall symptom load.

In its topical form, Riachol is generally used to help with supportive management for localized superficial eye and ear infections. This application contributes to improved comfort during periods of heightened symptoms, helping to manage symptoms related to inflammatory or irritative states, such as ocular discharge and redness.

Quick Fact: Relief for Symptoms related to Inflammatory or Irritative States

Regulatory References

NIH StatPearls overview of Chloramphenicol indications

Eligibility and Restrictions for Use

Who can and cannot use Riachol?

Riachol (Chloramphenicol) is an antibiotic whose systemic use is strictly reserved by regulatory authorities for specific populations facing serious or life-threatening infections when safer alternatives are unsuitable.

Populations Who Must Not Use Riachol (Contraindications)

Individuals with a history of bone-marrow depression, severe blood dyscrasias, or a known hypersensitivity to the medicine.
Neonates and premature infants due to the specific, life-threatening risk of Gray Baby Syndrome.
Breastfeeding mothers and individuals late in pregnancy (near term).
Use for trivial infections (e.g., colds) or as a prophylactic agent is officially contraindicated.

Restricted and Conditional Use

Systemic use is generally established in adults and older children, but is restricted to severe infection contexts. Special regulatory caution is mandated for patients with impaired hepatic (liver) or renal (kidney) function, where close monitoring is necessary. The use of Riachol must also be avoided in patients receiving other medications that are known to suppress bone marrow function.

What should I know about interactions with other medicines?

Riachol (Chloramphenicol) interaction patterns are formally documented across three primary regulatory domains: pharmacokinetic inhibition, pharmacodynamic reinforcement, and interference with certain products. Official regulatory documentation states that Chloramphenicol is an inhibitor of hepatic cytochrome P450 enzymes, specifically CYP2C19 and CYP3A4. This pharmacokinetic interaction reduces the clearance of co-administered medicines that are substrates for these enzymes, potentially leading to increased plasma concentrations of the co-administered drug.

Documented Pharmacokinetic Interactions

Interaction Type	Interacting Substances	Official Outcome
Enzyme Inhibition (CYP)	Phenytoin, Phenobarbital, Oral Anticoagulants, Chlorpropamide, Tacrolimus, Cyclosporine	Increased plasma levels / reduced clearance of co-administered substance

The pharmacodynamic profile indicates that co-administration with other medicinal products known to cause bone marrow depression may result in an additive or reinforced risk of myelosuppression. This restriction is formally noted in labeling. Additionally, official regulatory documents state that combinations with live bacterial vaccines, such as the Typhoid vaccine, are restricted due to the potential for Chloramphenicol to interfere with the intended immunological response. The risk and severity of all documented drug interactions are officially noted to be heightened in patients with impaired hepatic or renal function due to reduced clearance.

Mechanism of Action

Riachol (Chloramphenicol) acts solely on the microbial level by interfering with the most fundamental biological process of the bacterial cell. This mechanism is highly targeted and leads directly to the cellular arrest of the pathogen.

Targeted Inhibition of Bacterial Protein Synthesis

Riachol exerts its action by binding reversibly to the 50S ribosomal subunit within the bacterial cell, specifically inhibiting the Peptidyl Transferase enzyme activity. This mechanism effectively blocks the formation of new peptide bonds, thereby halting the synthesis of essential bacterial proteins and arresting the pathogen's growth and multiplication. This molecular interference results in a predictable bacteriostatic effect, leading to a cessation of bacterial growth and facilitating clearance by host cellular processes.

Pathway Modulation and Mechanism Limitations

While the drug is highly effective at its molecular target, its mechanism is constrained by bacterial counter-pathways involving resistance. The effectiveness of ribosomal inhibition can be constrained by the bacterial enzyme Chloramphenicol Acetyltransferase (CAT), which chemically modifies and inactivates the drug, or by efflux pumps that actively expel the molecule from the cell. These resistance mechanisms represent limitations where the drug's biological effect is reduced, resulting in sub-inhibitory intracellular concentrations or inactivated drug molecules.

Dosage and Administration Information

Administration Overview

Riachol is typically administered in a clinical or home setting depending on the specific formulation prescribed. It is available in forms that require consistent timing to maintain steady levels of the active component within the biological system.

Preparation and Handling

Proper handling of the medication is essential to ensure its integrity. This includes following specific storage requirements, such as maintaining particular temperature ranges and protecting the product from direct light exposure. Prior to use, the medication should be inspected for any changes in color or the presence of particulate matter.

Routine Integration

For optimal integration into a healthcare routine, the medication is often used at the same time each day. This consistency helps in managing the physiological response to the treatment. If a scheduled application is missed, the standard procedure involves continuing with the next planned event rather than attempting to compensate for the interval.

Monitoring and Follow-up

Ongoing use of Riachol generally involves regular consultations with a healthcare provider. These sessions allow for the monitoring of the body's response and the adjustment of the long-term management plan. Users are encouraged to keep a record of their usage patterns to facilitate these discussions.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section outlines the types of research that have explored the use of the combination therapy. The information provided is solely descriptive of the studies' scope and findings, not a statement on therapeutic outcomes or suitability.

Research Summary

Research has explored an assessment of the speed and duration of observed changes in pain perception. Studies evaluated whether there was an association with a change in quality of life for participants experiencing chronic back pain. The profile of this combination was examined in various populations. Suitability for specific individuals is determined by a healthcare provider.

Clinical Trial Designs

The evidence base primarily consists of randomized, double-blind, placebo-controlled trials (RCTs).

Phase 3 RCTs: These large-scale studies are designed to compare the intervention against a placebo or an existing treatment. Research protocols typically follow participants for 12 to 24 weeks.
Open-Label Extension Studies: Following the initial RCT period, some participants transitioned into open-label extensions, where all received the active combination. Research examined the compound in individuals with severe nerve pain over longer durations (up to one year).

Key Areas of Investigation

1. Chronic Musculoskeletal Pain

Multiple studies investigated the combination's use in individuals with chronic lower back pain.

Study protocols frequently began with the lowest dose allowed for the compound.
The primary endpoints included standardized scales for self-reported pain intensity and functional limitations.
Research evaluated the relationship between the compound's administration and markers of joint inflammation.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Riachol (FAQ)

Q: What is the typical duration of treatment for an eye infection?

Official product information commonly indicates that the treatment period for Riachol eye drops is typically 5 days, and generally should not exceed one week in total. Official guidance suggests continuing the medicine for 48 hours after all symptoms have completely resolved.

Q: Does Riachol cause blurry vision or burning when applied?

Yes, local side effects specific to the eye are frequently reported in regulatory documents. These common effects may include a temporary burning or stinging sensation immediately after application, and a patient may also experience temporary blurred vision.

Q: Do I need a prescription to get Riachol eye drops?

The requirement for a prescription for Riachol can vary depending on the country or region. In the United States and Canada, official sources classify it as a prescription-only medicine. In certain other regions, specific low-strength ophthalmic formulations may be available directly from a pharmacist.

Q: What do I do if I get the eye drops in my mouth or accidentally swallow them?

The medicine is intended for external use in the eye only. Safety data sheets advise against attempting to induce vomiting if the eye drops are swallowed. Contacting a poison control center or seeking medical assistance is advised in this situation.

Q: How quickly will the eye infection start to feel better after starting Riachol?

Official patient information states that improvement should be observed within a specific timeframe. If improvement is not seen within 48 hours of starting treatment with Riachol, official guidance suggests consulting a healthcare provider.

Q: How long can I keep the Riachol bottle once it's been opened?

Official labeling specifies an 'in-use' stability period for the medicine once the container seal is broken. Any remaining portion of the medicine should be discarded six months after the bottle is first opened, regardless of the printed expiration date. Any remainder should also be discarded after the completion of the prescribed treatment course.

Q: Can I use Riachol if I have a liver or kidney problem?

Regulatory documents advise that caution is necessary for patients with impaired liver (hepatic) or kidney (renal) function. This is due to the potential for reduced clearance of the drug from the body, which could increase the risk of toxicity. Close monitoring may be required by a healthcare provider.

Q: I am pregnant, is it safe to use Riachol eye drops?

Official information states that it is not known whether the medicine can cause harm to a developing fetus. Therefore, its use during pregnancy is advised only if the potential benefit is determined to justify the potential risk. Systemic use of the drug is contraindicated (must be avoided) near term, or late in pregnancy.

How should Riachol be stored and disposed of?

Official Storage and Disposal Requirements for Riachol

This information is based strictly on the drug’s official regulatory labeling and prescribing information.

Storage Conditions

Riachol must be stored at controlled room temperature, typically maintained between 20 C and 25 C (68 F and 77 F). The product requires protection from light and moisture. To maintain potency, the drug must remain in its original, tightly closed container.

Requirement	Official Instruction
Temperature	Controlled Room Temperature
Prohibited	Do Not Freeze or Refrigerate
Protection	Protect from Light and Moisture

Stability and Handling

Once the container is opened, the medicine has an in-use stability period; discard any unused portion after 6 months, even if the printed expiration date has not yet passed. Always keep Riachol out of the reach of children.

Disposal Instructions

Unused or expired Riachol must be properly disposed of via an official drug take-back program or a designated collection site. Do not dispose of Riachol in household trash, and do not flush the medication down a toilet or drain, in accordance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Oman

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z